# ClinicalTrials.gov record NCT01483651

> PeptideScanner retained ClinicalTrials.gov record NCT01483651 at 2026-07-30T21:38:42.855Z. Its registry update date was 2016-03-29, and PeptideScanner's reviewed identity mapping was glucagon.

- Evidence object: `story:clinicaltrials-gov-nct01483651-glucagon:v1`
- Evidence domain: Clinical trials
- Date in source: 2016-03-29
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01483651-glucagon/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct01483651-glucagon-v1.json
- Content SHA-256: `dfeee7ef4849e07bf0ce47933f5d8253e706181dad9326f9eddf8f936faa8f50`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT01483651 ([`ctg-observation-nct01483651-2016-03-29-02fffab4cd06`](#source-ctg-observation-nct01483651-2016-03-29-02fffab4cd06))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01483651 at 2026-07-30T21:38:42.855Z. Its registry update date was 2016-03-29, and PeptideScanner's reviewed identity mapping was glucagon. ([`ctg-observation-nct01483651-2016-03-29-02fffab4cd06`](#source-ctg-observation-nct01483651-2016-03-29-02fffab4cd06))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01483651 at 2026-07-30T21:38:42.855Z. Its registry update date was 2016-03-29, and PeptideScanner's reviewed identity mapping was glucagon. ([`ctg-observation-nct01483651-2016-03-29-02fffab4cd06`](#source-ctg-observation-nct01483651-2016-03-29-02fffab4cd06))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01483651-2016-03-29-02fffab4cd06`](#source-ctg-observation-nct01483651-2016-03-29-02fffab4cd06))

## Sources

<a id="source-ctg-observation-nct01483651-2016-03-29-02fffab4cd06"></a>
- **ClinicalTrials.gov record NCT01483651 · retained source version 2016-03-29:02fffab4cd0667e1877f203dd28d78179f3541ba449abdd5d1f41dbacdcef91d** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01483651) (`ctg-observation-nct01483651-2016-03-29-02fffab4cd06`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01483651." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct01483651-glucagon-v1.json SHA-256: dfeee7ef4849e07bf0ce47933f5d8253e706181dad9326f9eddf8f936faa8f50.